Clinical data | |
---|---|
Trade names | Ryaltris |
Other names | GSP 301 |
AHFS/Drugs.com | Ryaltris |
License data | |
Pregnancy category |
|
Routes of administration | Nasal spray |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Olopatadine/mometasone, sold under the brand name Ryaltris, is a fixed-dose combination medication for the treatment of allergic rhinitis and rhinoconjunctivitis in adults and adolescents twelve years of age and older. [1] [4] [5] It contains olopatadine hydrochloride and mometasone furoate monohydrate. [1] [4] It is sprayed into the nose. [1] [4]
Common side effects include an unpleasant taste (dysgeusia). [1]
It was approved for medical use in Australia in December 2019, [1] [6] and in the United States in January 2022. [4]